This episode of the Pharmaron DMPK Insights Podcast Series features Scott Summerfield (Executive Director of Metabolism at Pharmaron) and John Mehl (consultant and previous director at GSK, and previous leader of the Protein MS group within the Bioanalysis, Immunogenicity and Biomarkers (BIB) department).
The pair explores the application of LC-MS techniques in the bioanalysis of biotherapeutics, discussing a range of topics, including:
- Mass spectrometry’s current impact in the biotherapeutics and biomarker space
- The use of LC-MS for specific biomarkers, the development of sensitive LC-MS assays, and the practical limits for achievable lower limits of quantification
- Upcoming developments in mass spectrometry and their advantage in analyzing biomarkers and biotherapeutics
Acknowledgments
Produced from materials originally authored by Pharmaron Beijing Co., Ltd.
About Pharmaron
Pharmaron (Stock Code: 300759.SZ/3759.HK) is a premier R&D service provider for the life sciences industry. Founded in 2004, Pharmaron has invested in its people and facilities, and established a broad spectrum of research, development and manufacturing service capabilities throughout the entire drug discovery, preclinical and clinical development process across multiple therapeutic modalities, including small molecules, biologics and CGT products. With over 17,000 employees, and operations in China, the U.S., and the U.K., Pharmaron has an excellent track record in the delivery of R&D solutions to its partners in North America, Europe, Japan and China.
Sponsored Content Policy: News-Medical.net publishes articles and related content that may be derived from sources where we have existing commercial relationships, provided such content adds value to the core editorial ethos of News-Medical.Net which is to educate and inform site visitors interested in medical research, science, medical devices and treatments.